<DOC>
	<DOCNO>NCT00244595</DOCNO>
	<brief_summary>The objective study describe candesartan cilexetil antihypertensive effect term achieve blood pressure hypertension control rate relationship subject characteristic antihypertensive efficacy , antihypertensive therapy ( candesartan cilexetil dose add-on treatment ) efficacy 1 year treatment period hypertensive child age 6 &lt; 17 year ; describe growth term height weight study population ; describe change neurocognition assess Full Scaled IQ score subset study subject ; determine pharmacokinetics candesartan hypertensive paediatric subject age 6 &lt; 17 year ; describe safety include adverse event adverse event necessitate study drug discontinuation include dose level dose duration relationship growth 1 year period hypertensive child age 6 &lt; 17 year .</brief_summary>
	<brief_title>Efficacy , Safety , &amp; Pharmacokinetics Candesartan Cilexetil Hypertensive Paediatric Subjects 6 &lt; 17 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>The subject must fulfil eligibility criterion participate Study 261A participate Study 261A meet follow criterion : Diagnosed untreated hypertension , Diagnosed treat , antihypertensive treatment least 2 day mean sit systolic blood pressure and/or sit diastolic blood pressure ≥ 95th percentile ≤ 20 mm Hg ( systolic ) and/or 10 ( diastolic ) mm Hg 95th percentile base heightadjusted chart age gender . Females childbearing potential ( postmenarche ) , must negative urine pregnancy test adhere pregnancy prevention method ( abstinence , barrier method plus spermicidal foam oral implanted contraceptive ) . A sign informed consent parent legal guardian assent form sign subject ( applicable ) . Any situation , clinical condition laboratory abnormality , opinion investigator sponsor , may interfere subject 's participation study would pose significant risk subject interfere assessment safety efficacy endpoint . Hypertension secondary coarctation aorta , pheochromocytoma , hyperthyroidism , Cushing 's syndrome , medication ( eg : corticosteroid ) . Known history bilateral renal artery stenosis , unilateral renal artery stenosis renal transplant . Glomerular filtration rate &lt; 50 mL/min base estimate value use Schwartz Formula . Nephrotic syndrome remission . Insulin dependent diabetes mellitus . Known bleeding , coagulation , platelet disorder could interfere blood sampling . Clinically significant valvular heart disease . Clinical diagnosis heart failure . Clinically significant arrhythmia ( eg , arrhythmia require medical therapy cause symptom ) . Second third degree AV block . Pregnant breastfeeding infant . Impaired liver function define either acute liver disease chronic liver disease persistent liver enzyme value great 1½ time upper limit reference range AST ALT . Known hypersensitivity ARBs . Unable antihypertensive medication ( diuretic , beta blocker , ACE Inhibitors , etc ) 6weeks . Inability discontinue medication may contribute elevate blood pressure e.g . systemic corticosteroid . Currently use , use within 14 day prior receive doubleblind medication , concomitant medication opinion investigator could negatively affect subject . Unable unwilling comply study requirement include blood sample swallow study drug tablet . Received investigational agent within 30 day prior receive study medication ( except Study 261A ) . Alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Pediatric hypertension</keyword>
	<keyword>Hypertension child</keyword>
</DOC>